WO2008091643A3 - Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie - Google Patents

Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie Download PDF

Info

Publication number
WO2008091643A3
WO2008091643A3 PCT/US2008/000890 US2008000890W WO2008091643A3 WO 2008091643 A3 WO2008091643 A3 WO 2008091643A3 US 2008000890 W US2008000890 W US 2008000890W WO 2008091643 A3 WO2008091643 A3 WO 2008091643A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
concurrent
antibody
combinations
immune suppressive
Prior art date
Application number
PCT/US2008/000890
Other languages
English (en)
Other versions
WO2008091643A2 (fr
Inventor
Birgit C. Schultes
Antoine A. Noujaim
Christopher F. Nicodemus
Original Assignee
Altarex Medical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp. filed Critical Altarex Medical Corp.
Publication of WO2008091643A2 publication Critical patent/WO2008091643A2/fr
Publication of WO2008091643A3 publication Critical patent/WO2008091643A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

L'invention concerne l'immunologie. Plus particulièrement, l'invention concerne l'utilisation d'agents ciblant / antagonisant des voies immunosuppressives concomitantes à une immunothérapie, ou concomitantes à une immunothérapie en combinaison avec une chimiothérapie.
PCT/US2008/000890 2007-01-23 2008-01-23 Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie WO2008091643A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89715507P 2007-01-23 2007-01-23
US60/897,155 2007-01-23

Publications (2)

Publication Number Publication Date
WO2008091643A2 WO2008091643A2 (fr) 2008-07-31
WO2008091643A3 true WO2008091643A3 (fr) 2009-12-23

Family

ID=39561939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000890 WO2008091643A2 (fr) 2007-01-23 2008-01-23 Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie

Country Status (1)

Country Link
WO (1) WO2008091643A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1907000T5 (pl) 2005-06-08 2020-11-16 Dana-Farber Cancer Institute Metody i kompozycje do leczenia infekcji przetrwałych
WO2009126817A2 (fr) 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Anticorps d'ige pour le traitement du cancer
WO2010063011A2 (fr) 2008-11-28 2010-06-03 Emory University Procédés pour le traitement d'infections et de tumeurs
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CN106794246B (zh) * 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
US20180221476A1 (en) * 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075110A2 (fr) * 2000-03-30 2001-10-11 Dyax Corp. Elements de liaison specifiques de la mucine-1 et techniques d'utilisation
WO2003034977A2 (fr) * 2001-10-26 2003-05-01 Altarex Medical Corp. Polytherapie pour le traitement de maladie
WO2003086041A2 (fr) * 2002-04-11 2003-10-23 Altarex Medical Corporation Agents de liaison et leur utilisation dans le ciblage de cellules tumorales
WO2003106497A1 (fr) * 2002-06-14 2003-12-24 Immunomedics, Inc. Anticorps monoclonal pam4 et son utilisation pour diagnostiquer et traiter un cancer du pancreas
WO2005123908A2 (fr) * 2004-06-14 2005-12-29 Daughters Of Charity Health System Extraordinary Nouvelles lignees cellulaires cancereuses et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075110A2 (fr) * 2000-03-30 2001-10-11 Dyax Corp. Elements de liaison specifiques de la mucine-1 et techniques d'utilisation
WO2003034977A2 (fr) * 2001-10-26 2003-05-01 Altarex Medical Corp. Polytherapie pour le traitement de maladie
WO2003086041A2 (fr) * 2002-04-11 2003-10-23 Altarex Medical Corporation Agents de liaison et leur utilisation dans le ciblage de cellules tumorales
WO2003106497A1 (fr) * 2002-06-14 2003-12-24 Immunomedics, Inc. Anticorps monoclonal pam4 et son utilisation pour diagnostiquer et traiter un cancer du pancreas
WO2005123908A2 (fr) * 2004-06-14 2005-12-29 Daughters Of Charity Health System Extraordinary Nouvelles lignees cellulaires cancereuses et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEUSER C ET AL: "An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, LONDON, GB, vol. 89, no. 6, 1 January 2003 (2003-01-01), pages 1130 - 1139, XP003013806, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
WO2008091643A2 (fr) 2008-07-31

Similar Documents

Publication Publication Date Title
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
EP2402373A3 (fr) Anticorps anti-EphB4 et procédés d'utilisation associés
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2011142858A3 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
WO2013123432A3 (fr) Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
WO2008118587A3 (fr) Applications thérapeutiques des cellules présentant un antigène humain par l'intermédiaire de la dectine.-1
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
WO2009158015A3 (fr) Antagonistes d’actriib et utilisations pour augmenter les taux d’érythrocytes
WO2011047087A3 (fr) Détection de protéine par l'intermédiaire de nanorapporteurs
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
WO2008076437A3 (fr) Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges
WO2012076293A9 (fr) Préparations contenant des polysiloxanes dotés de groupes azotés
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
BRPI0919412A8 (pt) composição imunonutricional e nutricional,agente intensificador de resposta imunológica e uso do mesmo.
WO2007127506A8 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
IL236601A0 (en) Antibodies against cytomegalovirus, preparations containing them and their uses
WO2007106915A3 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2008091643A3 (fr) Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie
IL206060A0 (en) Conjugates of anti-rg-1 antibodies, compositions comprising the same and uses thereof
WO2011050188A8 (fr) Anticorps anti-hepsine et procédés d'utilisation de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08724743

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08724743

Country of ref document: EP

Kind code of ref document: A2